Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2985 - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site

Breast Cancer


Jwa Hoon Kim


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


J.H. Kim1, S. Seo2, H. Im1, J.H. Lim1, W.R. Jo1, B.B. Im1, S.R. Park1

Author affiliations

  • 1 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 2 Oncology, Asan Medical Center, 05505 - Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2985


Proper evaluation and management of chemotherapy-related toxicity (CRT) is critical to cancer patients. We aimed to assess the clinical utility of STAF in patients with breast cancer receiving chemotherapy.


The STAF is a systematic form including common CRT lists and grades to help clinicians to assess CRT comprehensively as opposed to assessing CRT individually by cases. Using data from clinical data warehouse, the CRT profile was analyzed in patients with breast cancer receiving adjuvant or neoadjuvant therapy during two time periods; before (n = 1874) and after (n = 981) using STAF in the clinic at Asan Medical Center. The two cohorts were matched by age and chemotherapy, leaving conventional practice (A; n = 333) and STAF (B; n = 333) groups. The rates of unscheduled hospital utilization (outpatient department [OPD], emergency room [ER] and hospitalization) were compared between group A and B.


No significant differences were noted in baseline characteristics between the two groups, except for a higher proportion of patients living near the hospital in group A compared to group B (67.0 vs 56.2%; P = 0.004). The completion rate of planned chemotherapy was 96.7% and 97.6% (P = 0.704), and the rate of dose reduction was 12.3% and 10.8% (P = 0.473), respectively, in group A and B. The median dose intensity was lower in group A than group B (0.92 vs. 0.95; P < 0.001). Higher reporting of CRT was observed in group B (P < 0.001). Despite a similar rate of unscheduled hospital utilization during cycle 1, since cycle 2, group B had a lower frequency of unexpected OPD (3.3 vs 6.6%, P = 0.050) and ER visits (9.6 vs 16.8%, P = 0.006), and hospitalization (8.4 vs 12.6%; P = 0.077) than group A.Table:


Unscheduled utilization since cycle 2 of chemotherapyGroup A (n = 333, %)Group B (n = 333, %)P
OPD22 (6.6)11 (3.3)0.050
ER56 (16.8)32 (9.6)0.006
Hospitalization42 (12.6)28 (8.4)0.077


Using the STAF may facilitate to capture CRT in clinical practice and reduce the rates of unscheduled hospital utilization in patients with breast cancer receiving adjuvant or neoadjuvant therapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Korean Foundation for Cancer Research.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.